Targeted Oncology4d
Extended SGX301 Treatment Shows Positive Results in Early-Stage CTCL
SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.
Scientific Research Publishing5d
Efficacy of School-Based Interventions to Manage Psychosocial Problems of an Adolescent: A Clinical Case Study ()
Efficacy of School-Based Interventions to Manage Psychosocial Problems of an Adolescent: A Clinical Case Study. Open Journal ...
FDA Accepts LEQEMBI (Lecanemab-Irmb) Biologics License Application For Subcutaneous Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...